ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales. Full year 2011 revenues, including license revenues, royalties and research agreements, increased 284% over 2010 figures. Access attributes growth in revenues to increased adoption of MuGard, as well as significant expansion by pharmacy benefit managers and payers to include MuGard in their benefit plans for reimbursement.
Wednesday morning, the Company will present at the Cowen and Company 32nd Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA. Mr. Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation updating investors on recent commercial advancements within its lead program for oral mucositis, MuGard, and other product programs.
Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer